163 related articles for article (PubMed ID: 18505966)
1. The taxane limbo: how low can we go?
Hudis C; Dang C
J Natl Cancer Inst; 2008 Jun; 100(11):761-3. PubMed ID: 18505966
[No Abstract] [Full Text] [Related]
2. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Herceptin and taxanes.
Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
[TBL] [Abstract][Full Text] [Related]
4. Taxane-based therapy for breast cancer: combination or sequential therapy?
Sparano JA; Rajdev L
Cancer Invest; 2000; 18(5):498-500. PubMed ID: 10834036
[No Abstract] [Full Text] [Related]
5. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Konecny GE; Thomssen C; Lück HJ; Untch M; Wang HJ; Kuhn W; Eidtmann H; du Bois A; Olbricht S; Steinfeld D; Möbus V; von Minckwitz G; Dandekar S; Ramos L; Pauletti G; Pegram MD; Jänicke F; Slamon DJ
J Natl Cancer Inst; 2004 Aug; 96(15):1141-51. PubMed ID: 15292386
[TBL] [Abstract][Full Text] [Related]
6. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
7. Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Kümmel S; Paepke S; Huober J; Schem C; Untch M; Blohmer JU; Eiermann W; Gerber B; Hanusch C; Hilfrich J; Jackisch C; Schneeweiss A; Denkert C; Engels K; Klare P; Fasching PA; von Minckwitz G; Burchardi N; Loibl S
Eur J Cancer; 2017 Oct; 84():1-8. PubMed ID: 28768217
[TBL] [Abstract][Full Text] [Related]
8. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
9. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
10. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
11. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
Valero V; Hortobagyi GN
J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
[No Abstract] [Full Text] [Related]
12. [From conquering metastatic disease to adjuvant therapy: clinical evolution of docetaxel in breast cancer].
Cartenì G
Tumori; 2001; 87(6):A1-5. PubMed ID: 11995695
[No Abstract] [Full Text] [Related]
13. [Role of taxanes in treatment of breast cancer].
Gorbunova VA; Besova NS
Vopr Onkol; 2004; 50(4):492-500. PubMed ID: 15605777
[No Abstract] [Full Text] [Related]
14. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.
Bedard PL; Di Leo A; Piccart-Gebhart MJ
Nat Rev Clin Oncol; 2010 Jan; 7(1):22-36. PubMed ID: 19997076
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
17. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
[TBL] [Abstract][Full Text] [Related]
18. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
19. [Paclitaxel in therapy of breast carcinoma. Value and perspectives].
Klaassen U; Seeber S
Med Klin (Munich); 1996 Dec; 91 Suppl 2():7-10. PubMed ID: 9082172
[No Abstract] [Full Text] [Related]
20. Docetaxel: today's results and tomorrow's promises.
Hortobagyi GN
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):11-4. PubMed ID: 9364535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
